Pleiotropic ABC efflux transporter that shows a strong substrate specificity for the azole class of drugs such as lotrimazole (CLT), fluconazole (FLC), itraconazole (ITC), ketoconazole (KTC), posaconazole (POS), tebuconazole (TEBZ), and voriconazole (VRC) (Probable) (PubMed:22509997, PubMed:23580559, PubMed:24123268, PubMed:28264842, PubMed:32209680). Is also able to transport rhodamine 6G (R-6G), a known substrate for many ABC transporters (PubMed:32209680). Required for normal pathogenesis in a Galleria mellonella (greater wax moth) infection model (PubMed:24123268). ATP + fluconazole(in) + H2O = ADP + fluconazole(out) + H(+) + phosphate ATP + H2O + itraconazole(in) = ADP + H(+) + itraconazole(out) + phosphate ATP + H2O + voriconazole(in) = ADP + H(+) + phosphate + voriconazole(out) The efflux inhibitor FK506 impairs the transport activity. Expression is positively regulated by the atrR transcription factor (PubMed:28052140). Expression is induced upon voriconazole treatment (PubMed:16622700, PubMed:24123268). Expression is increased in clinical azole-resistant isolates (PubMed:23580559, PubMed:32209680). In particular F20140, F18304 and F18454 show over 25-fold greater basal expression levels, whereas F19980 (7.2-fold), F20063 (6.5-fold), F20451 (3.6-fold), F18454 (5.1-fold) and F15483 (2.1-fold) also show significantly raised levels of basal expression (PubMed:23580559). Leads to decreased azole resistance, including itraconazole, posaconazole and voriconazole. Belongs to the ABC transporter superfamily. ABCG family. PDR (TC 3.A.1.205) subfamily.